The findings strongly indicate that selective RKIP inducers could hold promise for treating both NF2 syndrome and an NF2-deficient malignant peripheral nerve sheath tumor (MPNST) [104]. This evidence concerns the gene NF2 and malignant peripheral nerve sheath tumor.